Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2024
0mins
Source: Yahoo Finance
Financial Performance: Evolus Inc reported a 22% increase in net revenue for Q3 2024, totaling $61.1 million, while facing a non-GAAP operating loss of $6.7 million and a decrease in cash position to $85 million.
Market Position and Future Plans: The company expanded its product portfolio with the approval of Estyme in Europe and plans to launch Evolysse in the U.S. by September 2025, despite concerns about market softness affecting performance.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EOLS is 19.25 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.900
Low
18.00
Averages
19.25
High
20.00
Current: 4.900
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
